

Ioline D Henter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534630/publications.pdf>

Version: 2024-02-01

46
papers

3,162
citations

201674

27
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

4156
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Resolution of Suicidal Ideation After a Single Infusion of an <i>N</i> -Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1605-1611.	2.2	487
2	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. <i>Neuropsychopharmacology</i> , 2012, 37, 1526-1533.	5.4	262
3	Glutamatergic Modulators: The Future of Treating Mood Disorders?. <i>Harvard Review of Psychiatry</i> , 2010, 18, 293-303.	2.1	203
4	Targeting the Glutamatergic System to Treat Major Depressive Disorder. <i>Drugs</i> , 2012, 72, 1313-1333.	10.9	181
5	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. <i>Pharmaceuticals</i> , 2010, 3, 19-41.	3.8	168
6	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. <i>Lancet Psychiatry</i> , 2020, 7, 1064-1074.	7.4	149
7	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. <i>EJNMMI Research</i> , 2018, 8, 57.	2.5	144
8	Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 119-139.	9.4	140
9	New targets for rapid antidepressant action. <i>Progress in Neurobiology</i> , 2017, 152, 21-37.	5.7	118
10	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 119-135.	2.1	116
11	The neurotrophic and neuroprotective effects of psychotropic agents. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 333-348.	3.7	100
12	Defining anxious depression: a review of the literature. <i>CNS Spectrums</i> , 2013, 18, 252-260.	1.2	83
13	Novel glutamatergic agents for major depressive disorder and bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 678-687.	2.9	77
14	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. <i>CNS Drugs</i> , 2021, 35, 527-543.	5.9	74
15	Glutamatergic Modulators in Depression. <i>Harvard Review of Psychiatry</i> , 2018, 26, 307-319.	2.1	70
16	The effects of early and sustained intervention on the long-term morbidity of schizophrenia. <i>Journal of Psychiatric Research</i> , 1998, 32, 169-177.	3.1	69
17	Serotonin-1A receptors in major depression quantified using PET: Controversies, confounds, and recommendations. <i>NeuroImage</i> , 2012, 59, 3243-3251.	4.2	69
18	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 8-21.	2.1	58

#	ARTICLE	IF	CITATIONS
19	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , 2019, 24, 2033-2043.	6.4	57
20	Animal models of suicide-trait-related behaviors. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 165-173.	8.7	56
21	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. <i>Molecular Psychiatry</i> , 2021, 26, 4085-4095.	7.9	48
22	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 417-425.	2.1	42
23	Presynaptic Glutamatergic Dysfunction in Bipolar Disorder. <i>Biological Psychiatry</i> , 2010, 67, 1007-1009.	1.3	40
24	Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 787-800.	5.4	37
25	Ketamine treatment for depression: a review. <i>Discover Mental Health</i> , 2022, 2, 9.	2.0	37
26	PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. <i>Journal of Neuroinflammation</i> , 2020, 17, 140.	7.2	35
27	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. <i>Advances in Pharmacology</i> , 2018, 82, 163-185.	2.0	32
28	The long-term effects of placebo in patients with chronic schizophrenia. <i>Biological Psychiatry</i> , 1999, 46, 1092-1105.	1.3	28
29	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	4.8	26
30	Early intervention in bipolar disorder, part I: clinical and imaging findings. <i>Microbial Biotechnology</i> , 2008, 2, 122-135.	1.7	24
31	Early intervention in bipolar disorder, part II: therapeutics. <i>Microbial Biotechnology</i> , 2008, 2, 136-146.	1.7	22
32	Neurobiological biomarkers of response to ketamine. <i>Advances in Pharmacology</i> , 2020, 89, 195-235.	2.0	21
33	Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model. <i>Neuroscience Letters</i> , 2014, 559, 163-168.	2.1	16
34	Are 24-hour motor activity patterns associated with continued rapid response to ketamine?. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2739-2748.	2.2	14
35	A role for PKC in mediating stress-induced prefrontal cortical structural plasticity and cognitive function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17613-17614.	7.1	11
36	Lithium revisited: savings brought about by the use of lithium, 1970-1991. <i>Psychiatric Quarterly</i> , 2001, 72, 149-166.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Bipolar Disorder: A Neurobiological Synthesis. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 5, 331-340.	1.7	7
38	Partial Rodent Genetic Models for Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 5, 89-106.	1.7	6
39	A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants. <i>Progress in Neurobiology</i> , 2021, 206, 102140.	5.7	6
40	Not So Fast. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	6
41	Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia. <i>Journal of Nuclear Medicine</i> , 2022, 63, 53S-59S.	5.0	6
42	Adverse events during a placebo phase for inpatients with chronic schizophrenia. <i>Biological Psychiatry</i> , 2001, 50, 487-492.	1.3	3
43	Authors'™ Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status". <i>CNS Drugs</i> , 2022, 36, 205-206.	5.9	3
44	Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. <i>Journal of Psychiatric Research</i> , 2017, 86, 55-57.	3.1	2
45	Dr Salvatore and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1698-1700.	2.2	0
46	Potential Novel Treatments in Bipolar Depression. <i>Milestones in Drug Therapy</i> , 2016, , 259-285.	0.1	0